Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia

耐受性 安慰剂 痴呆 不利影响 医学 精神运动性躁动 随机对照试验 临床终点 阿尔茨海默病 内科学 麻醉 疾病 病理 替代医学
作者
Daniel Lee,M Słomkowski,Nanco Hefting,Dalei Chen,Klaus Groes Larsen,Eva Kohegyi,Mary Hobart,Jeffrey L. Cummings,George T. Grossberg
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:80 (12): 1307-1307 被引量:117
标识
DOI:10.1001/jamaneurol.2023.3810
摘要

Importance: Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need of an efficacious, safe, and well-tolerated treatment. Objective: To confirm the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer dementia. Design, Setting, and Participants: This randomized clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that ran from May 2018 to June 2022 at 123 clinical trial sites in Europe and the United States. Participants included patients with agitation in Alzheimer dementia in a care facility or community-based setting. Stable Alzheimer disease medications were permitted. Interventions: In this 2-arm trial, patients were randomized to receive oral brexpiprazole or placebo (2:1 ratio) for 12 weeks. Within the brexpiprazole arm, patients were further randomized to receive fixed doses of 2 mg/d or 3 mg/d in a 1:2 ratio. Main Outcomes and Measures: The primary end point was change in Cohen-Mansfield Agitation Inventory total score (which measures the frequency of 29 agitated behaviors) from baseline to week 12 for brexpiprazole, 2 or 3 mg, vs placebo. Safety was assessed by standard measures, including treatment-emergent adverse events. Results: A total of 345 patients were randomized to receive brexpiprazole (n = 228) or placebo (n = 117); completion rates were 198 (86.8%) for brexpiprazole and 104 (88.9%) for placebo. Mean (SD) age was 74.0 (7.5) years, and 195 of 345 patients were female (56.5%). Patients receiving brexpiprazole, 2 or 3 mg (n = 225), demonstrated statistically significantly greater improvement than those taking placebo (n = 116) in Cohen-Mansfield Agitation Inventory total score from baseline to week 12 (brexpiprazole baseline, 80.6, mean change, -22.6; placebo baseline, 79.2, mean change, -17.3; least-squares mean difference, -5.32; 95% CI, -8.77 to -1.87; P = .003; Cohen d effect size, 0.35). No treatment-emergent adverse events had an incidence of 5% or more with brexpiprazole and greater incidence than placebo. The proportion of patients who discontinued because of adverse events was 12 of 226 (5.3%) for brexpiprazole and 5 of 116 (4.3%) for placebo. Conclusions and Relevance: In this study, patients with Alzheimer dementia who took brexpiprazole, 2 or 3 mg, showed a statistically significant improvement vs placebo in agitation over 12 weeks. Brexpiprazole was generally well tolerated over 12 weeks in this vulnerable patient population. Trial Registration: ClinicalTrials.gov Identifier: NCT03548584.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小陈陈完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
2秒前
2秒前
2秒前
yishu完成签到,获得积分10
3秒前
酷酷柚子发布了新的文献求助10
3秒前
舒舒的应助被闫霄溯采纳,获得10
3秒前
ICH完成签到,获得积分10
3秒前
hhh发布了新的文献求助10
4秒前
巅峰囚冰完成签到,获得积分10
4秒前
xu1227发布了新的文献求助10
4秒前
简单豆芽完成签到,获得积分10
4秒前
4秒前
4秒前
灵巧绿海发布了新的文献求助10
5秒前
5秒前
AKTAO发布了新的文献求助10
5秒前
5秒前
7秒前
刘威完成签到,获得积分10
7秒前
柚子瓤发布了新的文献求助10
7秒前
聪慧若风完成签到,获得积分10
7秒前
vicluwang完成签到,获得积分10
8秒前
Hiker发布了新的文献求助10
9秒前
9秒前
饱满的醉冬完成签到 ,获得积分10
9秒前
a1313发布了新的文献求助10
10秒前
10秒前
apple发布了新的文献求助10
10秒前
ljj发布了新的文献求助10
11秒前
Rocky完成签到,获得积分10
11秒前
NexusExplorer的应助被惠惠采纳,获得10
11秒前
zenzero完成签到,获得积分10
11秒前
12秒前
12秒前
深情安青的应助被酷酷柚子采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166